Bright Minds price target raised to $145 from $115 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Bright Minds (DRUG) to $145 from $115 and keeps a Buy rating on the shares. The firm says the BREAKTHROUGH Phase 2 data “de-risks” BMB-101 and establishes 5-HT2C agonist as potentially best-in-class. H.C. Wainwright increased its probability of success for the absence epilepsy program to 60% from 25%, reflecting what it believes is a “significant efficacy signal and validation from the trial.”